TXMD: TherapeuticsMD, Inc. Stock

by  •  • Comments Off on TXMD: TherapeuticsMD, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 10.14
Enterprise Value ($M) 5.08
Book Value ($M) 27.37
Book Value / Share 2.36
Price / Book 0.37
NCAV ($M) 0.81
NCAV / Share 0.07
Price / NCAV 12.56

Profitability (mra)
Return on Invested Capital (ROIC) -0.06
Return on Assets (ROA) -0.05
Return on Equity (ROE) -0.08

Liquidity (mrq)
Quick Ratio 2.37
Current Ratio 2.37

Balance Sheet (mrq) ($M)
Current Assets 12.26
Assets 38.82
Liabilities 11.45
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1.76
Operating Income -3.49
Net Income -2.18
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.73
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-12 13G Clearline Capital LP 5.50 -0.22

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-11 12,245 22,956 53.34
2025-04-10 5,333 16,466 32.39
2025-04-09 6,727 17,780 37.83
2025-04-08 15,635 27,032 57.84
2025-04-07 10,757 19,082 56.37

(click for more detail)

Similar Companies
TSHA – Taysha Gene Therapies, Inc. TSVT – 2seventy bio, Inc.
TWST – Twist Bioscience Corporation TYRA – Tyra Biosciences, Inc.
UBX – Unity Biotechnology, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: TherapeuticsMD